BeiGene, Ltd. (6160.HK)

HKD 105.9

(-1.4%)

Total Assets Summary of BeiGene, Ltd.

BeiGene, Ltd.'s latest annual total assets in 2023 was 5.8 Billion USD , down -9.0% from previous year.
BeiGene, Ltd.'s latest quarterly total assets in 2024 Q2 was 5.71 Billion USD , up 0.79% from previous quarter.
BeiGene, Ltd. reported annual total assets of 6.37 Billion USD in 2022, down -26.22% from previous year.
BeiGene, Ltd. reported annual total assets of 8.64 Billion USD in 2021, up 54.37% from previous year.
BeiGene, Ltd. reported quarterly total assets of 5.66 Billion USD for 2024 Q1, down -2.37% from previous quarter.
BeiGene, Ltd. reported quarterly total assets of 5.8 Billion USD for 2023 Q4, up 5.08% from previous quarter.

Annual Total Assets Chart of BeiGene, Ltd. (2023 - 2013)

Historical Annual Total Assets of BeiGene, Ltd. (2023 - 2013)

Year	Total Assets	Total Assets Growth
2023	5.8 Billion USD	-9.0%
2022	6.37 Billion USD	-26.22%
2021	8.64 Billion USD	54.37%
2020	5.6 Billion USD	247.38%
2019	1.61 Billion USD	-28.33%
2018	2.24 Billion USD	114.98%
2017	1.04 Billion USD	157.87%
2016	405.81 Million USD	247.55%
2015	116.76 Million USD	117.76%
2014	53.62 Million USD	354.49%
2013	11.79 Million USD	0.0%

Year	Total Assets	Total Assets Growth
2024 Q2	5.71 Billion USD	0.79%
2024 Q1	5.66 Billion USD	-2.37%
2023 Q4	5.8 Billion USD	5.08%
2023 Q1	5.95 Billion USD	-6.62%
2023 Q3	5.52 Billion USD	-3.56%
2023 FY	5.8 Billion USD	-9.0%
2023 Q2	5.72 Billion USD	-3.83%
2022 Q4	6.37 Billion USD	-5.15%
2022 Q3	6.72 Billion USD	-8.84%
2022 FY	6.37 Billion USD	-26.22%
2022 Q2	7.37 Billion USD	-8.02%
2022 Q1	8.02 Billion USD	-7.22%
2021 Q3	5.28 Billion USD	-4.3%
2021 Q1	5.82 Billion USD	3.93%
2021 Q4	8.64 Billion USD	63.55%
2021 Q2	5.52 Billion USD	-5.1%
2021 FY	8.64 Billion USD	54.37%
2020 Q1	4.06 Billion USD	152.26%
2020 Q2	3.9 Billion USD	-4.03%
2020 Q4	5.6 Billion USD	0.62%
2020 FY	5.6 Billion USD	247.38%
2020 Q3	5.56 Billion USD	42.61%
2019 Q4	1.61 Billion USD	-14.29%
2019 FY	1.61 Billion USD	-28.33%
2019 Q2	2.15 Billion USD	-1.01%
2019 Q3	1.88 Billion USD	-12.52%
2019 Q1	2.17 Billion USD	-3.44%
2018 Q2	1.65 Billion USD	-3.22%
2018 FY	2.24 Billion USD	114.98%
2018 Q3	2.4 Billion USD	45.64%
2018 Q4	2.24 Billion USD	-6.6%
2018 Q1	1.7 Billion USD	63.3%
2017 FY	1.04 Billion USD	157.87%
2017 Q4	1.04 Billion USD	-0.25%
2017 Q3	1.04 Billion USD	121.33%
2017 Q1	376.72 Million USD	-7.17%
2017 Q2	473.97 Million USD	25.81%
2016 Q2	251.23 Million USD	-5.28%
2016 Q4	405.81 Million USD	72.37%
2016 Q3	235.42 Million USD	-6.29%
2016 Q1	265.22 Million USD	127.15%
2016 FY	405.81 Million USD	247.55%
2015 Q1	- USD	-100.0%
2015 Q3	135.6 Million USD	-0.99%
2015 Q4	116.76 Million USD	-13.9%
2015 FY	116.76 Million USD	117.76%
2015 Q2	136.96 Million USD	0.0%
2014 Q4	53.62 Million USD	0.0%
2014 FY	53.62 Million USD	354.49%
2013 FY	11.79 Million USD	0.0%

Peer Total Assets Comparison of BeiGene, Ltd.

Name	Total Assets	Total Assets Difference
Uni-Bio Science Group Limited	409.99 Million HKD	-1315.948%
CK Life Sciences Int'l., (Holdings) Inc.	11.24 Billion HKD	48.386%